Analysis of differentially expressed genes between TRCC and normal kidneys in Sun et al study confirmed overexpression of MET, in contrast to AXL and VEGFR.27 The activity of a selective MET inhibitor tivantinib has been tested in MiT associated tumors including only 6 TRCC patients. The gene discussed is MET; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.